NAMD sent a letter to the Health Resources and Services Administration (HRSA) and the Centers for Medicare and Medicaid Services (CMS) to share our recent white paper discussing operational challenges in Medicaid’s interaction with the 340B drug discount program. The white paper is available here. Read the full letter here.

Continue reading

This NAMD working paper describes the challenges confronted by Medicaid programs in their interactions with the 340B drug discount program, including inconsistent guidance from federal agencies, the growth of contract pharmacy arrangements, and issues with Medicaid managed care programs. The paper also offers several recommendations to address the identified challenges. Read the full paper here.

Continue reading

Today the National Association of Medicaid Directors sent the attached letter to the leaders of the Senate Finance and HELP and House Energy & Commerce and Ways & Means committees regarding the current situation with break through prescription drug treatments. The letter addresses the challenges presented by new hepatitis C treatments. It focuses on issues […]

Continue reading

The National Association of Medicaid Directors released a public memo which discusses average acquisition cost (AAC) methodologies for Medicaid prescription drug reimbursement. The memo also provides an update on CMS’s progress finalizing average market price-based Federal Upper Limits (AMP-based FULs) for prescription drugs. Read the full memo here.

Continue reading

NAMD sends letter to CMS Deputy Administrator and Director of Center for Medicaid & CHIP Services Cindy Mann providing additional comments to the Federal Upper Limit (FUL) files and the National Average Drug Acquisition Cost (NADAC) survey. The comments pertain to the Medicaid Outpatient Prescription Drug regulation. Read the full letter here.

Continue reading